Stem cell trial can re-start
August 2, 2010Research and Development Geron, Stem cells, spinal injury, stem cell
US regulators have given the green light for the first human trial of an embryonic stem cell therapy to resume. …
Working with a changing NHS
August 2, 2010Sales and Marketing HCA, NHS, commissioning, market access
The first Healthcare Communications Association (HCA) forum of 2010 took place this April in London and looked at the central …
Doctors.net.uk boosts team
August 2, 2010Sales and Marketing appointment, doctors.net, sales and marketing
UK healthcare professional network Doctors.net.uk has appointed Marie Pickford and Ben Mansfield to its pharmaceutical team. Marie joins in a …
NICE halts Prolia appraisal
August 2, 2010Sales and Marketing Amgen, NICE, Prolia
NICE says it has been forced to terminate a review of Amgen’s bone density drug Prolia after the US biotech …
Digital Pharma: Novartis game takes aim at ticks
July 30, 2010Medical Communications Digital Pharma blog, Novartis, digital patients, disease awareness campaigns, encephalitis
Novartis has launched a new online game to raise awareness of the risks posed by ticks and how to avoid …
Fleishman-Hillard adds new digital director
July 30, 2010Medical Communications Fleishman, appointment, medical communications
Dean Russell has joined Fleishman-Hillard London as its new director of digital. He has a wealth of experience in developing …
Wellcome Trust signs £45m Indian collaboration
July 30, 2010Research and Development India, Wellcome, em, emerging markets
UK medical research charity the Wellcome Trust and the Indian government are to jointly develop a range of innovative and …
Cancer Research UK facility celebrates first GMP batch
July 30, 2010Manufacturing and Production Biotherapeutic, Cancer Research UK, biologics
Cancer Research UK has produced the first batch of product from its recently-completed biologics manufacturing unit, and hopes to release …
FDA recommends Brilinta
July 30, 2010Sales and Marketing 2010 financials, AstraZeneca, Brillinta, Q2
FDA advisors have voted in favour of AstraZeneca’s antiplatelet drug Brilinta, which is currently seeking a licence for the reduction …
Dr Bruce Burlington joins AZ board
July 30, 2010Research and Development, Sales and Marketing AstraZeneca, appointment, research and development, sales and marketing
AstraZeneca has appointed former FDA staffer Dr Bruce Burlington to its board as a non-executive director. Dr Burlington spent 17 …
JWT wins Pfizer account, denies it’s ‘Viagra 2’
July 30, 2010Medical Communications JWT, Pfizer, viagra
UK advertising agency JWT London has won an account from Pfizer, but played down media reports it had been appointed …
Sanofi’s blockbusters take a hit
July 29, 2010Sales and Marketing 2010 financials, Genzyme, Q2, Sanofi-Aventis
Generic pressures, European pricing pressures and the impact of the US health reforms combined to dent Sanofi-Aventis’s growth in the …
Contract research news in brief
July 29, 2010Research and Development CRO, LAB Research, Microsoft, PPD, PharmaNet, QPS, Selvita
Icon reports that new business wins rose healthily in the second quarter, plus there’s an alliance between PPD and Microsoft …
RSA expands European teams
July 29, 2010Business Services appointment, business services, rsa
Life sciences executive search and interim management firm RSA has made series of new appointments to some of the European …
Robert Thomson joins Photosound
July 29, 2010Medical Communications Photosound, appointment, medical communications
UK brand communcations agency Photosound has appointed Robert Thomson as head of digital product development. He has over 15 years’ …
Cardio3 BioSciences appoints Dr Atta Behfar
July 29, 2010Research and Development Cardio3, appointment, research and development
Belgium biotech company Cardio3 BioSciences has appointed Dr Atta Behfar as director for advanced research. He will spend a year …
UK lags behind Europe on innovative cancer drugs
July 29, 2010Sales and Marketing Cancer, market access
The UK has been ranked as one of the worst countries when it comes to uptake of new cancer drug …
Merck KGaA’s oral MS therapy gains US priority review
July 29, 2010Sales and Marketing Cladribine, MS, Merck KGaA
Merck’s cladribine has been granted a priority review status by the FDA in a move that could see it come …
Chiltern Announces its Financial Results for the Year Ended 31 March 2010
July 28, 2010Research and Development
Highlights• Revenues of £80.9 million, 9.8% ahead of the year ended March 2009. Of this, 1.5% is due to acquisitions, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
